GM Exercise: 30 Days · First 100 Customers · Biggest Risk
The instinct at a company delayed one year is to sprint. The correct instinct is to audit before you acquire a single customer — because EHRX's one-year delay means the product menu, website copy, and tech stack were designed for a regulatory environment that no longer exists. You can't build a growth machine on a cracked foundation.
Critical platform clarification: In the Remedy Place playbook, Qualiphy functions as an in-person IV therapy clearance tool — a nurse practitioner clears patients in real time before in-clinic treatment. This is meaningfully different from a telehealth Rx routing platform. Before any marketing spend goes live, confirm exactly what Qualiphy does in the EHRX telehealth context: is it the prescribing platform, a consult routing tool, or something else? If it's in-person clearance only, EHRX needs a different telehealth Rx infrastructure for a DTC model. This is the single most important operational assumption to verify in Week 1.
"Ready to launch" is a checklist, not a feeling. Borrowed from the Remedy Place playbook's distinction between substantial completion and operational readiness: EHRX is substantially complete. The 30 days closes the gap. Do not run a single paid ad until the full patient journey has been completed end-to-end by a real person — without a break. The funnel has never been tested under real patient conditions. That test is the deliverable of the 30 days.
The first 100 customers are not a paid media problem. They are a trust and funnel-proof problem. EHRX needs social proof and operational confirmation before scaling spend. The strategy is layered: anchor on zero-CAC warm channels first, then paid, then the unconventional channel that competitors have no credibility to play in.
| Channel | Target | Est. Spend | Implied CAC | Rationale |
|---|---|---|---|---|
| Extension Health email / in-clinic referral | 25–30 | $0–500 | ~$10–20 | Warm, already converted on Dr. Kuo's protocols. Front desk QR code + segmented email. Lowest CAC in the stack. |
| Dr. Kuo organic social | 10–15 | $0 | $0 | Educational content on what peptides are — not treatment claims. Organic with real physician credibility. |
| Google Search (LegitScript-enabled) | 20–25 | $4K–6K | $200–280 | LegitScript certification is the competitive moat — most peptide operators cannot run Google ads. |
| Meta / Instagram (paid) | 15–20 | $3K–5K | $200–300 | Target: 35–60, biohacking/longevity interests. Dr. Kuo video creative. Meta Lead Ads with first-party forms. |
| Longevity podcast native ads | 10–15 | $3K–5K | $250–400 | See unconventional channel below. |
| Blended (100 customers) | 100 | ~$10–16K | ~$100–160 | At $199/mo avg with ~70% gross margin. Payback on $130 blended CAC <1 month. |
*LTV assumes 75% 6-month retention with no empirical EHRX data yet. Treat as a working assumption, not a projection.
The risk: EHRX launches with a product menu that is largely illegal to compound in April 2026. This is not a generic "regulatory risk." It is a specific, confirmed, verifiable problem with the existing EHRX formulary — and it is the most likely reason the business was delayed, and the most likely thing that kills it in Year 1 if not addressed in the first week.
The EHRX website currently features BPC-157, CJC-1295, and Ipamorelin as lead products. All three are prohibited from compounding under current FDA 503A rules. Here is the confirmed status:
| Peptide | 503A Status | Compoundable? | Notes |
|---|---|---|---|
| BPC-157 | Prohibited | No | Category 2 (significant safety concerns). Not on 503A Bulks List. FDA may take enforcement action. |
| CJC-1295 | Prohibited | No | Reviewed by PCAC Dec 2024 — rejected for inclusion. Remains prohibited for compounding. |
| Ipamorelin | Prohibited | No | Reviewed by PCAC Oct 2024, rejected. Also Category 2 on 503B bulks list. |
| Semaglutide | Prohibited (503B) | 503A only / borderline | FDA declared shortage over Feb 2025. Under intense scrutiny. Not a viable anchor. |
| Sermorelin | Permissible | Yes | USP monograph. Closest legal substitute for CJC-1295/Ipamorelin protocols. |
| Gonadorelin | Permissible | Yes | Category 1 in 2025 updates. FDA-approved (LutrePulse). Men's hormonal health. |
| PT-141 | Conditional | Patient-specific only | FDA-approved (Vyleesi). Compoundable with documented significant difference need. |
| NAD+ | Permissible | Yes | GRAS status. Already part of Extension Health's in-clinic offering. |
The failure mode is specific and immediate. Any one of these events, in a business delayed a year, is potentially existential:
The contrarian upside: Every Medvi-type competitor who gets hit with an FDA warning letter, every gray-market peptide platform that loses LegitScript certification, every compounding pharmacy that gets shut down — each is a market-share transfer event for EHRX. The business that survives is the business that positioned as credible before the enforcement wave, not the one that scrambles to be compliant after it. EHRX already has the infrastructure to be that business. The work is protecting it.
The deliberate inclusion of both the MEDVI playbook (how to build a $1.8B acquisition machine fast) and the red-flag article (FDA warnings, fake testimonials, class action suit) is not an invitation to replicate MEDVI for peptides. It is a test of whether the incoming GM can identify the correct lesson: MEDVI proved the demand exists. The winners will be the ones who build trust while competitors burn it.
EHRX has every structural advantage MEDVI lacks — a real physician, a real clinic, real LegitScript certification, a real pharmacy — and exactly zero of MEDVI's credibility problems. The job is to protect those assets, not to move fast enough to jeopardize them.
EHRX has every structural advantage MEDVI lacks — a real physician, a real clinic, real LegitScript certification, a real pharmacy — and exactly zero of MEDVI's credibility problems.
The job is to protect those assets, not to move fast enough to jeopardize them.